Aardvark Therapeutics Pauses Phase 3 HERO Trial for ARD-101

Key Facts

1Aardvark Therapeutics announced a voluntary pause of the Phase 3 HERO trial for ARD-101.

2The trial evaluates the efficacy and safety of ARD-101 for treating hyperphagia in patients with Prader-Willi Syndrome (PWS).

3The company is listed on Nasdaq under the ticker AARD.

Aardvark Therapeutics (Nasdaq: AARD) has announced a voluntary pause of its Phase 3 HERO clinical trial. The trial was designed to evaluate the efficacy and safety of its lead candidate, ARD-101, for treating hyperphagia in patients with Prader-Willi Syndrome (PWS). While the company did not disclose specific clinical or safety reasons for the pause, the move introduces significant uncertainty for investors. This delay in a late-stage trial typically impacts the timeline for regulatory approval and eventual commercialization. Consequently, shares of AARD may face downward pressure as the market reacts to the potential setback in its primary development program. The company continues to monitor the situation as it assesses the next steps for the ARD-101 clinical program.